drugset / Trial / NCT01833897
NMDA Antagonists in Bipolar Depression
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cycloserine will serve as an effective therapy following ketamine treatment.
Timeline
- Start
- 2013-03
- Primary completion
- 2014-07
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cycloserine | Small molecule | 1000 mg | Oral |
| Subject | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |
| Background | Fluoxetine | Small molecule | — | — |
| Background | Lurasidone | Small molecule | 60 mg | — |
| Background | Olanzapine | Small molecule | — | — |
| Background | Quetiapine | Small molecule | 300 mg | — |